No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 30 of the 40 quarters in the window, leaving 10 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 9.3x · 10Y median 9.9x · 48th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:06:18.707Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:06:18.707Z. Latest historical point 2025-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:06:18.707Z. Latest historical point 2025-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:06:18.707Z. Latest historical point 2025-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:06:18.707Z. Latest historical point 2025-08-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Dare Bioscience, Inc. (DARE) stock was $0.85 as of Oct 6, 2026, 10:02 AM EDT, up 0.84% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -61.1% · 3-year avg -46.5%/yr · 5-year avg -46.4%/yr
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Biotechnology · San Diego, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.14
Revenue Est.
$2.02M
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.30
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DARE | $12.74M | $0.85 | +0.84% | -61.15% | -46.35% | -39.10% | N/A |
| 2CLRB | $13.26M | $1.66 | -0.60% | -49.83% | -60.51% | -55.35% | vs DARE |
| 3IRIX | $12.12M | $0.70 | +1.48% | -42.35% | -38.13% | -26.14% | vs DARE |
| 4HIND | $13.48M | $1.92 | -0.52% | -74.83% | -92.93% | N/A | vs DARE |
| 5LTRN | $11.83M | $0.93 | -1.34% | -76.97% | -37.05% | N/A | vs DARE |
| 6CTSO | $11.81M | $3.76 | -5.17% | -79.67% | -52.26% | -28.72% | vs DARE |
forward FY estimate
N/A
$187546.00
vs Estimate
$1667.00
Consensus Rating
Based on 3 analysts
Average Price Target
$8.33
+880.2% upside
Low
$5.00
Current
$0.85
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.42 | $-0.14 | $0.16 | 2 |
| Quarter ending Dec 2026 | $-0.28 | $-0.23 | $-0.19 | 2 |
| Quarter ending Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Quarter ending Jun 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.04 | $-0.78 | $-0.52 | 2 |
| FY 2027 | $-0.61 | $-0.41 | $-0.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.02M | $2.02M | $2.02M | 2 |
| Quarter ending Dec 2026 | $359333.00 | $359333.00 | $359333.00 | 2 |
| Quarter ending Mar 2027 | $1.67M | $1.67M | $1.67M | 1 |
| Quarter ending Jun 2027 | $1.99M | $1.99M | $1.99M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $248388.00 | $2.72M | $5.19M | 2 |
| FY 2027 | $6.16M | $8.86M | $12.04M | 1 |
